Measuring success in HS treatment from the physician's and the patient's perspective [0.03%]
从医生和患者的角度衡量HS治疗的成功标准
Georgios Nikolakis,Monika Arenbergerova,Zeljko Mijuskovic et al.
Georgios Nikolakis et al.
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease with substantial quality-of-life impact. Accurate measurement of treatment success requires validated instruments capturing both physician-assessed disease a...
Knowing the disease, avoiding the clinic: A surgeon's lived experience with hidradenitis suppurativa [0.03%]
知病避医——一位手术医生的hidradenitis suppurativa患病经历
İsmail Hakkı Ünal,Musab Yeniköy,Ayşenur Botsalı
İsmail Hakkı Ünal
Pegylated interferon-α-2a in severe Adamantiades-Behçet disease: A series of seven cases [0.03%]
阿德马尼迪斯-贝赫切特综合征重症患者使用聚乙二醇干扰素α-2a治疗：7例报告分析
Andreas Altenburg,Eleni Kourtellari,Lothar Krause et al.
Andreas Altenburg et al.
Cutaneous T-cell lymphoma and dupilumab for atopic dermatitis: Practical guidance for a clinical conundrum [0.03%]
皮肤T细胞淋巴瘤与 Dupixent（Dupilumab）治疗特应性皮炎：临床困境的实用指导方针
Anna De Benedetto,Kathleen A Mannava
Anna De Benedetto
Two-year abrocitinib in atopic dermatitis: Are we reaching the new targets? [0.03%]
阿布西替尼治疗特应性皮炎两年：我们达成了新的目标吗？
Axel De Greef,Marie Baeck
Axel De Greef
Michela Starace,Bertrand Richert
Michela Starace
Beyond the numbers: Understanding and acting on gender gaps in academic dermatology [0.03%]
超越数字：理解并应对学术皮肤病学中的性别差距
Marie-Aleth Richard,Myrto Trakatelli
Marie-Aleth Richard
Diagnosing skin conditions in patients with skin of colour: Is colour the only challenge? [0.03%]
有色皮肤患者的皮肤病诊断：颜色是唯一的挑战吗？
Emanuele Scala,Maria Angeliki Gkini
Emanuele Scala
Managing the unmanageable? Practical guidance for lichen planopilaris [0.03%]
应对无法应对的局面？毛囊红斑外狼疮的治疗建议
Cristian Papara,Petra Rózsa,Rolland Gyulai
Cristian Papara
Biological treatment in atopic dermatitis-Lessons from the BioDay registry [0.03%]
生物制剂在特应性皮炎治疗中的应用——BioDay登记处的启示
Weronika Zysk,Magdalena Trzeciak
Weronika Zysk